Literature DB >> 3142872

Characterization of the interaction in vivo of tissue-type plasminogen activator with liver cells.

J Kuiper1, M Otter, D C Rijken, T J van Berkel.   

Abstract

The interaction in vivo of 125I-labeled tissue-type plasminogen activator (t-PA) with the rat liver and the various liver cell types was characterized. Intravenously injected 125I-t-PA was rapidly cleared from the plasma (t1/2 = 1 min), and 80% of the injected dose associated with the liver. After uptake, t-PA was rapidly degraded in the lysosomes. The interaction of 125I-t-PA with the liver could be inhibited by preinjection of the rats with ovalbumin or unlabeled t-PA. The intrahepatic recognition site(s) for t-PA were determined by subfractionation of the liver in parenchymal, endothelial, and Kupffer cells. It can be calculated that parenchymal cells are responsible for 54.5% of the interaction of t-PA with the liver, endothelial cells for 39.5%, and Kupffer cells for only 6%. The association of t-PA with parenchymal cells was not mediated by a carbohydrate-specific receptor and could only be inhibited by an excess of unlabeled t-PA, indicating involvement of a specific t-PA recognition site. The association of t-PA with endothelial cells could be inhibited 80% by the mannose-terminated glycoprotein ovalbumin, suggesting that the mannose receptor plays a major role in the recognition of t-PA by endothelial liver cells. An excess of unlabeled t-PA inhibited the association of 125I-t-PA to endothelial liver cells 95%, indicating that an additional specific t-PA recognition site may be responsible for 15% of the high affinity interaction of t-PA with this liver cell type. It is concluded that the uptake of t-PA by the liver is mainly mediated by two recognition systems: a specific t-PA site on parenchymal cells and the mannose receptor on endothelial liver cells. It is suggested that for the development of strategies to prolong the half-life of t-PA in the blood, the presence of both types of recognition systems has to be taken into account.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3142872

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Recognition of chylomicron remnants and beta-migrating very-low-density lipoproteins by the remnant receptor of parenchymal liver cells is distinct from the liver alpha 2-macroglobulin-recognition site.

Authors:  M C van Dijk; G J Ziere; W Boers; C Linthorst; M K Bijsterbosch; T J van Berkel
Journal:  Biochem J       Date:  1991-11-01       Impact factor: 3.857

2.  Endocytosis and intracellular processing of tissue-type plasminogen activator by rat liver cells in vivo.

Authors:  E Stang; J Krause; W Seydel; T Berg; N Roos
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

Review 3.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

4.  Uptake of lactosylated low-density lipoprotein by galactose-specific receptors in rat liver.

Authors:  M K Bijsterbosch; T J Van Berkel
Journal:  Biochem J       Date:  1990-08-15       Impact factor: 3.857

Review 5.  Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors:  D M Lutomski; M Bottorff; K Sangha
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

6.  Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.

Authors:  U Martin; S Fischer; U Kohnert; U Opitz; R Rudolph; G Sponer; A Stern; K Strein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

7.  Random PCR mutagenesis screening of secreted proteins by direct expression in mammalian cells.

Authors:  G C Rice; D V Goeddel; G Cachianes; J Woronicz; E Y Chen; S R Williams; D W Leung
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

8.  39-kD protein inhibits tissue-type plasminogen activator clearance in vivo.

Authors:  I Warshawsky; G Bu; A L Schwartz
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

9.  Evidence for carbohydrate-independent endocytosis of tissue-type plasminogen activator by liver cells.

Authors:  E Stang; N Roos; M Schlüter; T Berg; J Krause
Journal:  Biochem J       Date:  1992-08-01       Impact factor: 3.857

Review 10.  Carbohydrate analysis throughout the development of a protein therapeutic.

Authors:  Elizabeth Higgins
Journal:  Glycoconj J       Date:  2009-11-04       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.